Risk factor
Very high price volatility
Profitability factor
Greatly overvalued vs peers
About
Echo IQ Limited provides cardiac diagnostics support solution in Australia. The company offers artificial intelligence-assisted diagnostics technology that enhance the diagnosis of structural heart disease, as well as Aortic Stenosis. It primarily serves physicians, health systems, and patients. The company was formerly known as Houston We Have Limited and changed its name to EchoIQ Limited in December 2021. Echo IQ Limited is based in Sydney, Australia.
Company Valuation
From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks.
Target Price
The average target price of EIQ.AX is 0.69 and suggests 24% downside potential. Usually, this means a SELL recommendation among investment firms, or a recommendation to d
Buy
Sell